Publications by authors named "Omeed Alipour"

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for strategies to diagnose and manage GERD. This document was developed using the Grading of Recommendations Assessment, Development, and Evaluation framework and serves as an update to the 2014 ASGE guideline on the role of endoscopy in the management of GERD. This updated guideline addresses the indications for endoscopy in patients with GERD as well as in the emerging population of patients who develop GERD after sleeve gastrectomy or peroral endoscopic myotomy.

View Article and Find Full Text PDF
Article Synopsis
  • * It favors percutaneous endoscopic gastrostomy (PEG) over interventional radiology-guided options and recommends starting tube feeding within 4 hours post-procedure.
  • * Additionally, the guideline states that antiplatelet medications usually don’t need to be stopped before PEG, while anticoagulant management should involve a team discussion considering bleeding and cardiovascular risks.
View Article and Find Full Text PDF
Article Synopsis
  • This clinical practice guideline from the ASGE offers evidence-based recommendations for using endoscopy to diagnose and manage pancreatic masses, focusing on needle selection and sample processing.
  • It advises the use of fine-needle biopsy (FNB) needles, particularly 22-gauge over 25-gauge, and recommends fork-tip or Franseen needle types, while suggesting against routine rapid on-site evaluation (ROSE) for initial tissue acquisitions.
  • For managing biliary obstructions and pain in unresectable cases, it recommends self-expandable metal stents (SEMSs) over plastic stents, with covered SEMSs preferred when malignancy is confirmed, and celiac plexus neurolysis (CPN) for abdominal pain.
View Article and Find Full Text PDF

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for the role of endoscopy in the management of chronic pancreatitis (CP). This document was developed using the Grading of Recommendations Assessment, Development and Evaluation framework. The guideline addresses effectiveness of endoscopic therapies for the management of pain in CP, including celiac plexus block, endoscopic management of pancreatic duct (PD) stones and strictures, and adverse events such as benign biliary strictures (BBSs) and pseudocysts.

View Article and Find Full Text PDF

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy provides an evidence-based approach for the role of therapeutic EUS in the management of biliary tract disorders. This guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation framework and addresses the following: 1: The role of EUS-guided biliary drainage (EUS-BD) versus percutaneous transhepatic biliary drainage (PTBD) in resolving biliary obstruction in patients after failed ERCP. 2: The role of EUS-guided hepaticogastrostomy versus EUS-guided choledochoduodenostomy in resolving distal malignant biliary obstruction after failed ERCP.

View Article and Find Full Text PDF

Background: Deep remission (DR) is a treatment target in IBD associated with reduced hospitalization and improved outcome. Randomized control trial (RCT) data demonstrates efficacy of anti-TNFα agents in achieving DR; however, real-world data (RWD) can provide information complementary to RCTs, specifically regarding treatment duration. In this systematic review with meta-analysis, we use real-world data (RWD) to determine rates of DR in IBD treated with anti-TNFα.

View Article and Find Full Text PDF

Background: Sarcopenia is associated with postoperative complications in inflammatory bowel disease. It has most commonly been defined using the skeletal muscle index, computed after analysis of cross-sectional muscle area at L3. Psoas muscle thickness normalized to height (PMTH), which is easier to derive, is a potential surrogate of SMI and sarcopenia in patients with cirrhosis and chronic pancreatitis.

View Article and Find Full Text PDF

Background And Aims: We conducted a systematic review and meta-analysis evaluating the relapse rate after therapeutic de-escalation in inflammatory bowel disease [IBD] patients who achieved deep remission [DR].

Methods: We searched MEDLINE, EMBASE, and major gastroenterology conferences up to July 2019 for studies reporting relapse in adult patients with DR who subsequently underwent therapeutic de-escalation. Eligible studies defined DR as at least a combination of clinical remission and mucosal healing/endoscopic remission.

View Article and Find Full Text PDF

The inflammatory bowel diseases (IBD) are a complex set of chronic gastrointestinal inflammatory conditions arising from the interplay of genetic and environmental factors. This study focuses on noncoding RNA transcripts as potential mediators of IBD pathophysiology. One particular gene, interferon γ-antisense 1 (), has been consistently observed to be elevated in the intestinal mucosa of patients with actively inflamed IBD versus healthy controls.

View Article and Find Full Text PDF

Background: Tumor necrosis factor alpha-induced protein 3 () is a multifunctional ubiquitin binding and editing enzyme that regulates inflammation. Genetic studies have implicated polymorphisms within the locus to the development of numerous immune-related diseases. This study evaluated the frequencies of single nucleotide polymorphism (SNPs) within the exonic regions of the gene and an associated point mutation from the Illumina array among a predominantly Hispanic cohort.

View Article and Find Full Text PDF

Introduction: Uremia results in a characteristic breath odor (uremic fetor) which is largely due to its high ammonia content. Earlier studies have shown a strong correlation between breath ammonia and blood urea levels and a 10-fold reduction in breath ammonia after hemodialysis in patients with chronic kidney disease. Potential sources of breath ammonia include: (i) local ammonia production from hydrolysis of urea in the oropharyngeal and respiratory tracts by bacterial flora, and (ii) release of circulating blood ammonia by the lungs.

View Article and Find Full Text PDF